<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-22 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-22</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-22</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-1.html">extraction-schema-1</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <p><strong>Paper ID:</strong> paper-243e8e824274e7bca88fb1a73439b3699380fddc</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/243e8e824274e7bca88fb1a73439b3699380fddc" target="_blank">Editorial: Concomitant pathogenic mutations in oncogene-driven subgroups: when next generation biology meets targeted therapy in NSCLC</a></p>
                <p><strong>Paper Venue:</strong> Frontiers in Oncology</p>
                <p><strong>Paper TL;DR:</strong> This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) and the use, distribution or reproduction in other forums is permitted, provided the original author and the copyright owner are credited and that the original publication in this journal is cited.</p>
                <p><strong>Paper Abstract:</strong> COPYRIGHT © 2023 Malapelle, Tabbò and Muscarella. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. TYPE Editorial PUBLISHED 22 June 2023 DOI 10.3389/fonc.2023.1239304</p>
                <p><strong>Cost:</strong> 0.022</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e22.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e22.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EGFR</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Epidermal Growth Factor Receptor activating mutations</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Canonical RTK driver in lung adenocarcinoma; activating point mutations (e.g., L858R, exon 19 deletions) that confer sensitivity to EGFR tyrosine kinase inhibitors.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>EGFR activating mutations (e.g., L858R, exon 19 deletions)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation / small indel (activating)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>EGFR / RTK-RAS-RAF pathway</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>response to targeted therapy (EGFR TKIs), genomic profiling cited in literature</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Sensitivity to EGFR TKIs (clinical responses) as described in foundational studies; functional activation of EGFR signaling (reviewed)</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Defines an oncogene-addicted NSCLC subgroup with meaningful responses to EGFR TKIs</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Responsive to EGFR tyrosine kinase inhibitors (multiple generations of TKIs)</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Next-generation sequencing (NGS) / targeted molecular testing (DNA-based); clinical genotyping</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Editorial: Concomitant pathogenic mutations in oncogene-driven subgroups: when next generation biology meets targeted therapy in NSCLC', 'publication_date_yy_mm': '2023-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e22.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e22.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EGFRex20ins</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>EGFR exon 20 insertions</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A subset of EGFR activating alterations (in-frame insertions in exon 20) associated with distinct therapeutic sensitivity and poorer outcomes to some EGFR TKIs.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>EGFR exon 20 insertions (EGFRex20ins)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>in-frame insertion / exon 20 insertion</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>EGFR / RTK-RAS-RAF pathway</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>clinical-genomic correlation (literature cited), response/resistance data to EGFR TKIs</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>TP53 co-mutations associated with worse prognosis in EGFRex20ins patients; associated with copy number gain instability and higher tumor mutational burden (per cited analyses)</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Poorer prognosis and reduced benefit from some second-/third-generation EGFR-TKIs in patients with TP53 co-mutations (as cited)</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>NGS on DNA/RNA from tissue (editorial notes NGS as gold standard)</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Editorial: Concomitant pathogenic mutations in oncogene-driven subgroups: when next generation biology meets targeted therapy in NSCLC', 'publication_date_yy_mm': '2023-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e22.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e22.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>ALK fusion</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Anaplastic Lymphoma Kinase gene rearrangements (e.g., EML4-ALK)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Gene fusions involving ALK (commonly EML4-ALK) that drive a subset of lung adenocarcinomas and are targetable with ALK inhibitors.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>ALK gene fusions (e.g., EML4-ALK)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>gene fusion / rearrangement</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>ALK / RTK-RAS-RAF pathway (RTK)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>response to targeted therapy (ALK TKIs), genomic profiling, structural/variant analyses</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Rearranged-positive NSCLC shows specific co-occurrence patterns (e.g., higher prevalence of CDKN2A/B loss with TP53 mutations or MYC amplification cited)</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Targetable by ALK tyrosine kinase inhibitors; variant-specific impact on resistance mechanisms noted (EML4-ALK variants influence resistance/outcomes)</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>NGS (DNA/RNA), fusion testing</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Editorial: Concomitant pathogenic mutations in oncogene-driven subgroups: when next generation biology meets targeted therapy in NSCLC', 'publication_date_yy_mm': '2023-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e22.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e22.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>ROS1</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>ROS1 rearrangements</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>ROS1 gene fusions define a distinct, targetable molecular class of lung cancers driven by RTK rearrangements.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>ROS1 gene rearrangements / fusions</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>gene fusion / rearrangement</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>ROS1 / RTK-RAS-RAF pathway (RTK)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling and response to targeted therapy (literature cited)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Described as a unique molecular class of lung cancers in cited work</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>ROS1 fusions are targetable with ROS1-directed TKIs (in literature)</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>NGS (RNA/DNA fusion testing)</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Editorial: Concomitant pathogenic mutations in oncogene-driven subgroups: when next generation biology meets targeted therapy in NSCLC', 'publication_date_yy_mm': '2023-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e22.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e22.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>RET fusions</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>RET gene rearrangements (e.g., KIF5B-RET)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Rearrangements involving RET are oncogenic drivers in a subset of lung adenocarcinomas; specific fusion partners (e.g., KIF5B) have been described.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>RET gene fusions (e.g., KIF5B-RET)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>gene fusion / rearrangement</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>RET / RTK-RAS-RAF pathway (RTK)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling, clinical characterization (literature cited)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>RET-rearranged tumors show co-occurrence patterns (references note CDKN2A/B loss, TP53 mutations, MYC amplification in rearranged-positive NSCLC)</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Targetable RET rearrangements (RET inhibitors described in literature)</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>NGS (RNA/DNA fusion panels)</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Editorial: Concomitant pathogenic mutations in oncogene-driven subgroups: when next generation biology meets targeted therapy in NSCLC', 'publication_date_yy_mm': '2023-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e22.5">
                <h3 class="extraction-instance">Extracted Data Instance 5 (e22.5)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>BRAF V600E</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>BRAF p.V600E mutation</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A canonical activating mutation in the RAF kinase (BRAF) that drives MAPK pathway activation and is targetable with BRAF plus MEK inhibitors.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>BRAF V600E (p.V600E)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation (activating)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>BRAF / RAS-RAF-MAPK pathway</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>clinical trial response to BRAF+MEK inhibitors (literature cited), genomic profiling</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Activates MAPK signaling clinically targetable (cited trial dabrafenib + trametinib)</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Responsive to combined BRAF and MEK inhibition (e.g., dabrafenib + trametinib in cited trial)</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>NGS / targeted sequencing</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Editorial: Concomitant pathogenic mutations in oncogene-driven subgroups: when next generation biology meets targeted therapy in NSCLC', 'publication_date_yy_mm': '2023-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e22.6">
                <h3 class="extraction-instance">Extracted Data Instance 6 (e22.6)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>BRAF non-V600</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Non-V600 BRAF driver mutations</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Less common BRAF mutations (non-V600) that can act as drivers in lung adenocarcinoma and may be targetable depending on molecular context.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>Non-V600 BRAF mutations (targetable non-V600 drivers)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutations (non-V600)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>BRAF / RAS-RAF-MAPK pathway</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic landscape analyses (literature cited)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Identified as potentially targetable non-V600 drivers in cited analyses (context-dependent)</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>NGS / targeted sequencing</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Editorial: Concomitant pathogenic mutations in oncogene-driven subgroups: when next generation biology meets targeted therapy in NSCLC', 'publication_date_yy_mm': '2023-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e22.7">
                <h3 class="extraction-instance">Extracted Data Instance 7 (e22.7)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>KRAS</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations including p.G12C</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Common driver mutations in lung adenocarcinoma activating RAS signaling; specific alleles (e.g., G12C) have targeted inhibitors developed.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>KRAS mutations (e.g., p.G12C)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation (activating)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>KRAS / RAS-RAF-MAPK pathway</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling, response to allele-specific inhibitor (literature cited)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>KRAS co-mutations include LKB1, KEAP1, ATM, RBM10 and TP53 inactivation which are associated with early metastasis, aggressive phenotype and altered therapy responses</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Allele-specific inhibitors exist (e.g., sotorasib for KRAS p.G12C cited)</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>NGS / targeted panels</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Editorial: Concomitant pathogenic mutations in oncogene-driven subgroups: when next generation biology meets targeted therapy in NSCLC', 'publication_date_yy_mm': '2023-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e22.8">
                <h3 class="extraction-instance">Extracted Data Instance 8 (e22.8)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>NTRK fusions</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Neurotrophic receptor tyrosine kinase (NTRK1-3) gene fusions</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Oncogenic gene fusions involving NTRK genes that are rare but actionable drivers in lung adenocarcinoma.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>NTRK gene fusions (oncogenic rearrangements)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>gene fusion / rearrangement</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>NTRK family / RTK pathway</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling and drug-sensitive rearrangements described in literature</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>NTRK fusions are targetable with approved NTRK inhibitors (cited as drug-sensitive in literature)</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>NGS (RNA fusion detection)</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Editorial: Concomitant pathogenic mutations in oncogene-driven subgroups: when next generation biology meets targeted therapy in NSCLC', 'publication_date_yy_mm': '2023-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e22.9">
                <h3 class="extraction-instance">Extracted Data Instance 9 (e22.9)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>NRG1 fusions</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Neuregulin 1 gene fusions (e.g., CD74-NRG1)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Rare gene fusions involving NRG1 that act as oncogenic drivers in subsets of lung adenocarcinoma and can activate ERBB receptors.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>NRG1 gene fusions (e.g., CD74-NRG1)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>gene fusion / rearrangement</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>NRG1 (ligand for ERBB family) / downstream RTK signaling</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic discovery (literature cited)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Potentially targetable via ERBB pathway inhibitors in literature (NRG1 fusions described as oncogenic)</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>NGS (RNA fusion detection)</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Editorial: Concomitant pathogenic mutations in oncogene-driven subgroups: when next generation biology meets targeted therapy in NSCLC', 'publication_date_yy_mm': '2023-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e22.10">
                <h3 class="extraction-instance">Extracted Data Instance 10 (e22.10)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>ERBB2</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>ERBB2 (HER2) intragenic kinase mutations</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Intragenic kinase domain mutations in ERBB2 (HER2) are oncogenic events in a subset of lung adenocarcinomas and are considered actionable in precision oncology.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>ERBB2 intragenic kinase mutations</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation / small indel (kinase domain)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>ERBB2 (HER2) / RTK-RAS-RAF pathway</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling (literature cited)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>ERBB2-mutant tumors are candidate for HER2-directed therapies (discussed in literature)</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>NGS (DNA-based sequencing)</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Editorial: Concomitant pathogenic mutations in oncogene-driven subgroups: when next generation biology meets targeted therapy in NSCLC', 'publication_date_yy_mm': '2023-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e22.11">
                <h3 class="extraction-instance">Extracted Data Instance 11 (e22.11)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>METex14</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>MET exon 14 skipping alterations</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Splice-altering events that delete exon 14 of MET, leading to MET activation and clinical sensitivity to MET inhibitors.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>MET exon 14 skipping (METex14)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>splicing alteration / exon skipping</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>MET / RTK-RAS-RAF pathway (RTK)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling and clinical correlation (literature cited)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Cited evidence that MET exon 14 activation confers clinical sensitivity to MET inhibitors</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>TP53 mutations are underrepresented in METex14 patients; MDM2 and CDK4 co-amplifications frequently observed and associated with unfavorable outcome (cited)</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Responsive to MET inhibitors (literature cited)</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>NGS (DNA/RNA splicing and sequencing), clinical molecular testing</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Editorial: Concomitant pathogenic mutations in oncogene-driven subgroups: when next generation biology meets targeted therapy in NSCLC', 'publication_date_yy_mm': '2023-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e22.12">
                <h3 class="extraction-instance">Extracted Data Instance 12 (e22.12)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>LKB1</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>STK11 / LKB1 loss-of-function mutations</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Tumor suppressor inactivated by mutations co-occurring with KRAS in lung adenocarcinoma and associated with aggressive clinical phenotypes and therapy resistance.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>STK11 (LKB1) loss-of-function mutations</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>loss-of-function point mutation / deletion</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>STK11/LKB1 (tumor suppressor) - linked to KRAS-driven biology</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>co-occurrence genomic analyses (literature cited)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Associated with early metastatic dissemination, tumor maintenance and aggressive clinical phenotype in KRAS mutant tumors (cited)</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Co-occurs with KRAS and associated with poor responses to chemotherapy, immunotherapy and targeted agents (cited)</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>NGS / genomic profiling</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Editorial: Concomitant pathogenic mutations in oncogene-driven subgroups: when next generation biology meets targeted therapy in NSCLC', 'publication_date_yy_mm': '2023-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e22.13">
                <h3 class="extraction-instance">Extracted Data Instance 13 (e22.13)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>KEAP1</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>KEAP1 mutations</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Co-occurring genomic alterations in KRAS-mutant lung adenocarcinoma associated with aggressive biology and therapy resistance.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>KEAP1 mutations (loss-of-function)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>loss-of-function mutation</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>KEAP1 (oxidative stress regulator) - co-mutated with KRAS</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic co-occurrence profiling (literature cited)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Linked to aggressive phenotype and early metastatic dissemination when co-occurring with KRAS (cited)</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Co-occurs with KRAS; implicated in poor outcomes to standard therapies</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>NGS / genomic profiling</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Editorial: Concomitant pathogenic mutations in oncogene-driven subgroups: when next generation biology meets targeted therapy in NSCLC', 'publication_date_yy_mm': '2023-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e22.14">
                <h3 class="extraction-instance">Extracted Data Instance 14 (e22.14)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>ATM</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>ATM mutations</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Genomic alterations in the DNA damage response pathway that are reported as co-occurring lesions in KRAS-mutant lung adenocarcinoma.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>ATM mutations</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation / loss-of-function</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>ATM (DNA damage response) - co-occurrence with KRAS</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic co-occurrence analyses (literature cited)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Listed among core co-mutated genes with KRAS linked to aggressive phenotypes</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>NGS / genomic profiling</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Editorial: Concomitant pathogenic mutations in oncogene-driven subgroups: when next generation biology meets targeted therapy in NSCLC', 'publication_date_yy_mm': '2023-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e22.15">
                <h3 class="extraction-instance">Extracted Data Instance 15 (e22.15)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>RBM10</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>RBM10 mutations</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>RNA-binding protein gene mutated as a co-occurrence event in KRAS-driven lung adenocarcinoma, implicated in tumor biology.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>RBM10 mutations</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation / loss-of-function</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>RBM10 (RNA-binding factor) - co-occurrence with KRAS</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>co-occurrence genomic analyses (literature cited)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Part of a set of core co-mutated genes in KRAS-mutant advanced lung adenocarcinoma linked to aggressive features</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>NGS / targeted sequencing</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Editorial: Concomitant pathogenic mutations in oncogene-driven subgroups: when next generation biology meets targeted therapy in NSCLC', 'publication_date_yy_mm': '2023-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e22.16">
                <h3 class="extraction-instance">Extracted Data Instance 16 (e22.16)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>TP53</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Tumor protein p53 (TP53) mutations</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Frequent tumor suppressor inactivation across NSCLC subgroups; impacts prognosis and therapy response when co-occurring with oncogenic drivers.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>TP53 mutations (inactivating)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation / loss-of-function</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>TP53 (tumor suppressor)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>co-occurrence analyses and prognostic correlation (literature cited)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>TP53 inactivation influences early-stage disease, chemo-refractoriness, and resistance to PD-1/PD-L1 therapies in certain contexts (cited)</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Underrepresented in some subgroups (e.g., METex14) but frequent in others; negative prognostic marker in EGFRex20ins patients and linked to genetic instability in ALK cases</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Associated with worse prognosis and altered therapy responses; specific therapeutic strategies not defined in editorial</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>NGS / genomic profiling</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Editorial: Concomitant pathogenic mutations in oncogene-driven subgroups: when next generation biology meets targeted therapy in NSCLC', 'publication_date_yy_mm': '2023-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e22.17">
                <h3 class="extraction-instance">Extracted Data Instance 17 (e22.17)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>CDKN2A/B loss</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>CDKN2A and CDKN2B homozygous deletion / loss</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Tumor suppressor locus loss frequently observed as co-occurring events in rearranged-positive NSCLC (ALK/ROS1/RET), associated with altered clinical biology.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>CDKN2A and CDKN2B loss (deletion)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>deletion / copy number loss</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>CDKN2A/CDKN2B (cell cycle regulators)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic co-occurrence profiling (literature cited)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>More prevalent in rearranged-positive NSCLC (ALK/ROS1/RET) per cited analyses</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>NGS / copy number analysis</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Editorial: Concomitant pathogenic mutations in oncogene-driven subgroups: when next generation biology meets targeted therapy in NSCLC', 'publication_date_yy_mm': '2023-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e22.18">
                <h3 class="extraction-instance">Extracted Data Instance 18 (e22.18)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>MYC amp</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>MYC amplification</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Recurrent oncogene amplification observed in ALK-translocated NSCLC and associated with genetic instability and TP53 mutations.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>MYC amplification</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>copy number amplification</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>MYC (oncogene)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling and association analyses (literature cited)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Associated with ALK-translocated NSCLC and a central role of TP53 mutations in the genetic instability leading to recurrent MYC amplification (cited)</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>NGS / copy number profiling</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Editorial: Concomitant pathogenic mutations in oncogene-driven subgroups: when next generation biology meets targeted therapy in NSCLC', 'publication_date_yy_mm': '2023-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e22.19">
                <h3 class="extraction-instance">Extracted Data Instance 19 (e22.19)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>MDM2 amp</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>MDM2 amplification</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>MDM2 copy number gain/amplification frequently co-occurs with MET exon 14 skipping and is suggested as an unfavorable outcome predictor.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>MDM2 amplification / copy number gain</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>copy number amplification</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>MDM2 (p53 regulator)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>co-occurrence and clinicopathological correlation (literature cited)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Frequent co-occurrence with MET exon 14 skipping; associated with unfavorable outcome (cited)</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>NGS / copy number analysis</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Editorial: Concomitant pathogenic mutations in oncogene-driven subgroups: when next generation biology meets targeted therapy in NSCLC', 'publication_date_yy_mm': '2023-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e22.20">
                <h3 class="extraction-instance">Extracted Data Instance 20 (e22.20)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>CDK4 amp</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>CDK4 amplification</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>CDK4 copy number gain/amplification observed to co-occur with MET exon 14 skipping and implicated as an unfavorable prognostic marker.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>CDK4 amplification / copy number gain</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>copy number amplification</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>CDK4 (cell cycle regulator)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>co-occurrence profiling and clinical correlation (literature cited)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Frequently co-occurs with MET exon 14 skipping and associated with unfavorable outcome (cited)</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>NGS / copy number analysis</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Editorial: Concomitant pathogenic mutations in oncogene-driven subgroups: when next generation biology meets targeted therapy in NSCLC', 'publication_date_yy_mm': '2023-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e22.21">
                <h3 class="extraction-instance">Extracted Data Instance 21 (e22.21)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EML4-ALK variant</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>EML4-ALK fusion variant</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Structural variants of the EML4-ALK fusion influence resistance mechanisms and clinical outcomes in ALK-positive lung cancer.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>EML4-ALK fusion variants</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>gene fusion variant (structural isoforms)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>EML4-ALK (fusion involving ALK RTK)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>variant-specific analyses and clinical correlation (literature cited)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Different EML4-ALK variants impact resistance mechanisms and clinical outcomes (cited)</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Variant-specific implications for resistance to ALK inhibitors (discussed in cited studies)</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>NGS (fusion/isoform analysis)</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Editorial: Concomitant pathogenic mutations in oncogene-driven subgroups: when next generation biology meets targeted therapy in NSCLC', 'publication_date_yy_mm': '2023-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Comprehensive molecular profiling of lung adenocarcinoma. <em>(Rating: 2)</em></li>
                <li>Co-Occurring genomic alterations in non-small-cell lung cancer biology and therapy. <em>(Rating: 2)</em></li>
                <li>Effects of Co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer. <em>(Rating: 2)</em></li>
                <li>Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. <em>(Rating: 2)</em></li>
                <li>Characterization of 298 patients with lung cancer harboring MET exon 14 skipping alterations. <em>(Rating: 1)</em></li>
                <li>Molecular landscape of BRAF-mutant NSCLC reveals an association between clonality and driver mutations and identifies targetable non-V600 driver mutations. <em>(Rating: 2)</em></li>
                <li>Tracking the evolution of non-Small-Cell lung cancer. <em>(Rating: 2)</em></li>
                <li>The evolution of lung cancer and impact of subclonal selection in TRACERx. <em>(Rating: 2)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>